287408-01-9

Upstream product

• 287408-00-8 1-{[4-(2-butynyloxy)phenyl]sulfonyl}-2-aziridinecarboxylic acid methyl ester 
• 540-51-2 2-bromoethanol 
• 287121-33-9 methyl 2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-3-hydroxypropanoate 

Downstream Products

• 287408-03-1 4-([4-(2-butynyloxy)phenyl]sulfonyl}-morpholine-3-carboxylic acid 
• 287408-02-0 4-([4-(2-butynyloxy)phenyl]sulfonyl}-morpholine-3-carboxylic acid,methyl ester 

Relevant academic research and scientific papers

Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates

The SAR of a series of potent sulfonamide hydroxamate TACE inhibitors bearing a butynyloxy P1′ group was explored. In particular, compound 5k has excellent in vitro potency against TACE enzyme and in cells, and oral activity in an in vivo model of TNF-α production and a collagen-induced arthritis model.

ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS

Compound of the formula (B) are useful in treating disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors

Compounds of the formula: are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.